Traumatic Brain InjuryPhase 4NCT05058677
Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury
A Phase 4 study testing aerosolized 2% lidocaine (20mg/ml), instilled 0.9% sodium chloride (NS) and instilled 2% lidocaine solution in people with Traumatic Brain Injury, run by The University of Texas Health Science Center, Houston at 1 site in United States.
Trial summary
The purpose of this study is to evaluate the effectiveness of nebulized lidocaine before Endotracheal suctioning (ETS) compared to instilled lidocaine and the effectiveness of aerosolized lidocaine versus instilled normal saline before ETS in attenuating the increase of intracranial pressure (ICP) in severe head… Read more about this study
- Who is it for?
- Ages Up to 16 years
- Conditions the study is for
- Traumatic Brain Injury
- What is being tested?
- aerosolized 2% lidocaine (20mg/ml), instilled 0.9% sodium chloride (NS) and instilled 2% lidocaine solution
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Nov 2021to 30 Jun 2025
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 16 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Patients admitted to the PICU of Memorial Hermann Children's Hospital
- Severe TBI with a Glasgow Coma Scale score 4-8
- Intubated and mechanically ventilated with an ICP monitor in place.
- Continuous invasive monitoring of arterial pressure
- Hemodynamically Stable, defined by normal blood pressure for age before the ETS. We will not exclude patients with norepinephrine to maintain goal blood pressures to maintain Cerebral perfusion pressure(CPP).
Who cannot join
- Patients with sustained ICP > 25 for more than 30 minutes mm Hg despite medical or neurosurgical intervention
- Moderate/Severe Acute respiratory distress syndrome (ARDS) with an oxygenation index > 8
- Pulmonary hemorrhage
- Patients receiving neuromuscular blockade
- Use of other vasopressors for other causes of shock (cardiogenic, hypovolemic and septic)
Trial locations and contacts
1 site in 1 country.
United States1 site
The University of Texas Health Science Center at Houston
Houston, Texas, 77030
About this study
The purpose of this study is to evaluate the effectiveness of nebulized lidocaine before Endotracheal suctioning (ETS) compared to instilled lidocaine and the effectiveness of aerosolized lidocaine versus instilled normal saline before ETS in attenuating the increase of intracranial pressure (ICP) in severe head injured children and to evaluate the feasibility of a trial involving instilled lidocaine and aerosolized lidocaine for the management of ETS and to evaluate the safety of nebulized lidocaine in traumatic brain injury (TBI) compared to instilled lidocaine and instilled sodium chloride (NS).
- Conditions
- Traumatic Brain Injury
- Being tested
- aerosolized 2% lidocaine (20mg/ml), instilled 0.9% sodium chloride (NS), instilled 2% lidocaine solution, Endotracheal Suctioning (ETS)
- Keywords
- lidocaine, brain injury, intracranial pressure
- Medical subject headings
- Brain Injuries, Traumatic, Brain Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
aerosolized 2% lidocaine (20mg/ml)Drug
The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
instilled 0.9% sodium chloride (NS)Drug
The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
instilled 2% lidocaine solutionDrug
The instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment.
Endotracheal Suctioning (ETS)Procedure or surgery
ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline).
| Study group | Role | What they receive |
|---|---|---|
| aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution | Experimental | Treatment will be performed before the endotracheal suctioning Receives: Drug: aerosolized 2% lidocaine (20mg/ml); Drug: instilled 0.9% sodium chloride (NS); Drug: instilled 2% lidocaine solution; Procedure: Endotracheal Suctioning (ETS) |
| aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution | Experimental | Treatment will be performed before the endotracheal suctioning Receives: Drug: aerosolized 2% lidocaine (20mg/ml); Drug: instilled 0.9% sodium chloride (NS); Drug: instilled 2% lidocaine solution; Procedure: Endotracheal Suctioning (ETS) |
| Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution | Experimental | Treatment will be performed before the endotracheal suctioning Receives: Drug: aerosolized 2% lidocaine (20mg/ml); Drug: instilled 0.9% sodium chloride (NS); Drug: instilled 2% lidocaine solution; Procedure: Endotracheal Suctioning (ETS) |
| Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine | Experimental | Treatment will be performed before the endotracheal suctioning Receives: Drug: aerosolized 2% lidocaine (20mg/ml); Drug: instilled 0.9% sodium chloride (NS); Drug: instilled 2% lidocaine solution; Procedure: Endotracheal Suctioning (ETS) |
| Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution | Experimental | Treatment will be performed before the endotracheal suctioning Receives: Drug: aerosolized 2% lidocaine (20mg/ml); Drug: instilled 0.9% sodium chloride (NS); Drug: instilled 2% lidocaine solution; Procedure: Endotracheal Suctioning (ETS) |
| Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine | Experimental | Treatment will be performed before the endotracheal suctioning Receives: Drug: aerosolized 2% lidocaine (20mg/ml); Drug: instilled 0.9% sodium chloride (NS); Drug: instilled 2% lidocaine solution; Procedure: Endotracheal Suctioning (ETS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline Intracranial Pressure (ICP) at 2, 5 and 15 Minutes.
A Codman Intraparenchymal Catheter will measure the ICP. The ICP will be transduced and measured numerically and continuously in real time on the patient's bedside monitor. ICP Values were recorded at baseline and at 2, 5, and 15 minutes after administration of aerosolized lidocaine, instilled saline solution, or instilled lidocaine solution. Change from baseline is calculated at post intervention time point.
Measured: Baseline and 2, 5, and 15 minutes post-intervention
Secondary outcomes (1)
Number of Patients With Worsening Respiratory Dynamics
This will be measured by increasing oxygenation index or worsening compliance, measured by any increase in the peak pressure for volume ventilated patients.
Measured: from baseline to up to 15 minutes after ETS
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2021
- Study start9 Nov 2021
- Primary completion30 Jun 2025
- Study completion30 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Traumatic Brain InjuryStudies of the same condition, open and under way.
- More trials run by The University of Texas Health Science Center, HoustonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Thao L Nguyen, The University of Texas Health Science Center, Houston
- Investigators
- Thao L Nguyen, DO, FAAP, Principal investigator, The University of Texas Health Science Center, Houston
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05058677
- Sponsor's protocol ID
- HSC-MS-21-0254
- Status last verified
- Jan 2026
- First submitted
- 16 Sep 2021
- Last updated
- 7 Aug 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Aerosolized Endotracheal Lidocaine to Avoid Intracranial Pressure Spikes in Patients With Severe Traumatic Brain Injury
- ClinicalTrials.gov ID
- NCT05058677
- Acronym / sponsor ID
- HSC-MS-21-0254
- Conditions
- Traumatic Brain Injury
- Keywords
- lidocaine, brain injury, intracranial pressure
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- The University of Texas Health Science Center, HoustonUniversity, hospital or other
- Study start
- 9 Nov 2021 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 28 Sep 2021 (actual)
- Results
- Posted 7 Aug 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effectiveness of nebulized lidocaine before Endotracheal suctioning (ETS) compared to instilled lidocaine and the effectiveness of aerosolized lidocaine versus instilled normal saline before ETS in attenuating the increase of intracranial pressure (ICP) in severe head injured children and to evaluate the feasibility of a trial involving instilled lidocaine and aerosolized lidocaine for the management of ETS and to evaluate the safety of nebulized lidocaine in traumatic brain injury (TBI) compared to instilled lidocaine and instilled sodium chloride (NS).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution | Experimental | Drug: aerosolized 2% lidocaine (20mg/ml), Drug: instilled 0.9% sodium chloride (NS), Drug: instilled 2% lidocaine solution, Procedure: Endotracheal Suctioning (ETS)Treatment will be performed before the endotracheal suctioning |
| aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution | Experimental | Drug: aerosolized 2% lidocaine (20mg/ml), Drug: instilled 0.9% sodium chloride (NS), Drug: instilled 2% lidocaine solution, Procedure: Endotracheal Suctioning (ETS)Treatment will be performed before the endotracheal suctioning |
| Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution | Experimental | Drug: aerosolized 2% lidocaine (20mg/ml), Drug: instilled 0.9% sodium chloride (NS), Drug: instilled 2% lidocaine solution, Procedure: Endotracheal Suctioning (ETS)Treatment will be performed before the endotracheal suctioning |
| Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine | Experimental | Drug: aerosolized 2% lidocaine (20mg/ml), Drug: instilled 0.9% sodium chloride (NS), Drug: instilled 2% lidocaine solution, Procedure: Endotracheal Suctioning (ETS)Treatment will be performed before the endotracheal suctioning |
| Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution | Experimental | Drug: aerosolized 2% lidocaine (20mg/ml), Drug: instilled 0.9% sodium chloride (NS), Drug: instilled 2% lidocaine solution, Procedure: Endotracheal Suctioning (ETS)Treatment will be performed before the endotracheal suctioning |
| Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine | Experimental | Drug: aerosolized 2% lidocaine (20mg/ml), Drug: instilled 0.9% sodium chloride (NS), Drug: instilled 2% lidocaine solution, Procedure: Endotracheal Suctioning (ETS)Treatment will be performed before the endotracheal suctioning |
Who may qualify
- Ages
- Up to 16 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Patients admitted to the PICU of Memorial Hermann Children's Hospital
- Severe TBI with a Glasgow Coma Scale score 4-8
- Intubated and mechanically ventilated with an ICP monitor in place.
- Continuous invasive monitoring of arterial pressure
- Hemodynamically Stable, defined by normal blood pressure for age before the ETS. We will not exclude patients with norepinephrine to maintain goal blood pressures to maintain Cerebral perfusion pressure(CPP).
Key exclusion criteria (5 listed)
- Patients with sustained ICP > 25 for more than 30 minutes mm Hg despite medical or neurosurgical intervention
- Moderate/Severe Acute respiratory distress syndrome (ARDS) with an oxygenation index > 8
- Pulmonary hemorrhage
- Patients receiving neuromuscular blockade
- Use of other vasopressors for other causes of shock (cardiogenic, hypovolemic and septic)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| aerosolized 2% lidocaine (20mg/ml)The aerosolized solution to be used is 2% lidocaine (20 mg/ml) at a dose of 1.5 mg/kg with a maximum volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The aerosolized solution will be administered with an Aerogen ultrasonic nebulizer, which is standard of care for administering aerosolized solutions in our pediatric intensive care unit (PICU).After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment. | Drug | Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution, Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine, Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine, Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution, aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution, aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution |
| instilled 0.9% sodium chloride (NS)The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment. | Drug | Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution, Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine, Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine, Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution, aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution, aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution |
| instilled 2% lidocaine solutionThe instilled 2 % lidocaine solution used will be 1.5 mg/kg, with a max volume of 3 ml or adjusted to a volume of 3 ml with addition of NS solution.The instilled solution will be given with a standard 3-5 ml syringe.After each treatment a 3-minute interval will be allowed prior to ETS and there will be a 4-6 hour wash out period between each treatment. | Drug | Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution, Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine, Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine, Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution, aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution, aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution |
| Endotracheal Suctioning (ETS)ETS will be performed in a single pass using a closed-system suctioning. Suction will be applied only on withdrawal of the catheter and fraction of inspired oxygen (FIO2) will remain at 100% for 60 seconds following suctioning and then returned to the preprocedural level (baseline). | Procedure or surgery | Instilled lidocaine solution then aerosolized lidocaine then instilled saline solution, Instilled lidocaine solution then instilled saline solution then aerosolized lidocaine, Instilled saline solution then Instilled lidocaine solution then aerosolized lidocaine, Instilled saline solution then aerosolized lidocaine then Instilled lidocaine solution, aerosolized lidocaine then Instilled lidocaine solution then instilled saline solution, aerosolized lidocaine then instilled saline solution then Instilled lidocaine solution |
Primary outcome
Change From Baseline Intracranial Pressure (ICP) at 2, 5 and 15 Minutes.
Time frame: Baseline and 2, 5, and 15 minutes post-intervention
A Codman Intraparenchymal Catheter will measure the ICP. The ICP will be transduced and measured numerically and continuously in real time on the patient's bedside monitor. ICP Values were recorded at baseline and at 2, 5, and 15 minutes after administration of aerosolized lidocaine, instilled saline solution, or instilled lidocaine solution. Change from baseline is calculated at post intervention time point.
1 secondary outcome
Number of Patients With Worsening Respiratory Dynamics
Time frame: from baseline to up to 15 minutes after ETS
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Traumatic Brain Injury
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
Enrolling by invitationPhase 1
Pilot Safety and Exploratory Efficacy of PSC-05 for the Treatment of Chronic Mild Traumatic Brain Injury
Mild Traumatic Brain Injury
RecruitingObservational study
Intracranial Pressure Monitoring in Moderate Traumatic Brain Injury
Moderate Traumatic Brain Injury
Not yet recruitingPhase 1
Nanopulse Laser Therapy
TBI (Traumatic Brain Injury)
RecruitingObservational study
Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence
Chronic Subdural Hematoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thao L Nguyen, DO, FAAP principal investigator
The University of Texas Health Science Center, Houston
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing aerosolized 2% lidocaine (20mg/ml), instilled 0.9% sodium chloride (NS) and instilled 2% lidocaine solution in people with Traumatic Brain Injury, run by The University of Texas Health Science Center, Houston at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Aug 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline Intracranial Pressure (ICP) at 2, 5 and 15 Minutes. (time frame: Baseline and 2, 5, and 15 minutes post-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.